Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Teva Pharmaceutical Industries ADR (TEVA)
Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,100,536
  • Shares Outstanding, K 1,120,406
  • Annual Sales, $ 14,925 M
  • Annual Income, $ -2,353 M
  • 60-Month Beta 1.18
  • Price/Sales 0.54
  • Price/Cash Flow 1.99
  • Price/Book 0.94
Trade TEVA with:

Options Overview Details

View History
  • Implied Volatility 36.16% ( -2.09%)
  • Historical Volatility 38.01%
  • IV Percentile 14%
  • IV Rank 10.30%
  • IV High 109.53% on 11/02/22
  • IV Low 27.73% on 05/30/23
  • Put/Call Vol Ratio 0.46
  • Today's Volume 11,231
  • Volume Avg (30-Day) 22,093
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 1,187,413
  • Open Int (30-Day) 1,118,862

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.54
  • Number of Estimates 6
  • High Estimate 0.57
  • Low Estimate 0.50
  • Prior Year 0.64
  • Growth Rate Est. (year over year) -15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.09 +2.05%
on 05/31/23
9.21 -21.50%
on 05/09/23
-1.57 (-17.84%)
since 05/02/23
3-Month
7.09 +2.05%
on 05/31/23
10.14 -28.70%
on 03/06/23
-2.73 (-27.41%)
since 03/02/23
52-Week
6.78 +6.65%
on 07/14/22
11.44 -36.83%
on 01/12/23
-2.29 (-24.05%)
since 06/02/22

Most Recent Stories

More News
Why Teva Pharmaceutical Stock Is Jumping Today

Investors are reacting positively to Teva's new growth strategy.

TEVA : 7.23 (+0.42%)
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

TEVA : 7.23 (+0.42%)
RCUS : 21.01 (+3.50%)
ALLO : 5.61 (+5.45%)
OCUP : 3.85 (-4.23%)
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript

TEVA earnings call for the period ending March 31, 2023.

TEVA : 7.23 (+0.42%)
Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of...

TEVA : 7.23 (+0.42%)
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced an...

TEVA : 7.23 (+0.42%)
Embecta (EMBC) to Report Q2 Earnings: What's in Store?

Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.

TEVA : 7.23 (+0.42%)
HSIC : 74.42 (+1.35%)
BIO : 372.36 (+0.27%)
EMBC : 27.34 (+1.71%)
Charles River (CRL) to Report Q1 Earnings: What's in Store?

Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.

TEVA : 7.23 (+0.42%)
HSIC : 74.42 (+1.35%)
CRL : 200.68 (+2.21%)
BIO : 372.36 (+0.27%)
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has...

TEVA : 7.23 (+0.42%)
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has...

TEVA : 7.23 (+0.42%)
Teva to Launch New Growth Strategy at Investor Day

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event...

TEVA : 7.23 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 7.43
2nd Resistance Point 7.34
1st Resistance Point 7.29
Last Price 7.23
1st Support Level 7.15
2nd Support Level 7.06
3rd Support Level 7.01

See More

52-Week High 11.44
Fibonacci 61.8% 9.66
Fibonacci 50% 9.11
Fibonacci 38.2% 8.56
Last Price 7.23
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar